Prescriptions for popular weight-loss drug Wegovy have soared in Korea, reaching nearly 400,000 just eight months after its launch. But doctors and health officials warn of reckless use far beyond the ...

Eli Lilly and Company (NYSE: LLY) is one of the best stocks to invest in for long-term growth. Eli Lilly and Company ...

Given the potential side effects of GLP-1 prescription drugs, many Utahns are seeking alternative methods to naturally boost ...

Eli Lilly's orforglipron could have a few advantages over a pill from Novo Nordisk, including a lack of dietary restrictions ...

The weight-loss drug Wegovy just got FDA approval to treat a common and serious liver condition known as MASH (Metabolic ...

COMMENT: The monthly cost of a private prescription exceeding £300 from next month is worrying news for the half a million ...

A Comeback Fueled by Resilience Danish pharmaceutical giant Novo Nordisk (NYSE:NVO) has been a trailblazer in the GLP-1 drug ...

With results from highly anticipated trials of Eli Lilly’s orforglipron and Viking Therapeutics’ VK2735 “underwhelming” ...

Each week, Cabandugama says adults taking GLP-1 medications should aim for 150 minutes of moderate intensity activities such ...

As Novo Nordisk's sales of its blockbuster weight-loss drug Wegovy boomed, the Danish drugmaker raced to expand manufacturing ...

No one stays on top forever. It’s a lesson that Ozempic maker Novo Nordisk may be painfully learning about. The Danish ...

With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...